PD1-based signal transduction molecules, CAR-T cells and their applications

By designing signal transduction molecules containing the extracellular domain of PD1 and the intracellular co-stimulatory domain of 4-1BB, and combining them with CD28 co-stimulatory molecules, CAR-T cells with PD1-BB chimeric receptors were constructed. This solved the problems of immune escape and insufficient persistence of CAR-T cells in the treatment of B-cell malignancies, and achieved strong effector function and persistent tumor killing effect.

CN123062584APending Publication Date: 2026-11-10XUZHOU MEDICAL UNIVERSITY
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202510589049.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-08
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing CAR-T cells have problems with immune escape and insufficient persistence when treating B-cell malignancies. In particular, CAR-T cells containing CD28 co-stimulatory molecules have high initial activation intensity but poor persistence, while CAR-T cells containing 4-1BB co-stimulatory molecules have low initial activation level and low secretion of cytokines.

Method used

A signal transduction molecule containing the extracellular domain, hinge region, and transmembrane region of the PD1 molecule, as well as an intracellular co-stimulatory domain derived from 4-1BB, was designed to convert the inhibitory signal of PD1/PD-L1 into a T cell activating signal. By combining the advantages of the CD28 co-stimulatory molecule, B7-H3-28ζ-CAR-T cells carrying the PD1-BB chimeric receptor were constructed to enhance tumor killing ability and prolong their in vivo survival time.

Benefits of technology

CAR-T cells, which reduce or prevent immune escape and possess strong effector function and persistence, can effectively kill tumor cells and prolong their survival time in the body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005392641580000011
    Figure HDA0005392641580000011
  • Figure HDA0005392641580000012
    Figure HDA0005392641580000012
  • Figure HDA0005392641580000021
    Figure HDA0005392641580000021
Patent Text Reader

Abstract

This invention provides a PD1-based signal transduction molecule, CAR-T cells, and their applications. Specifically, it provides a signal transduction molecule constructed by replacing the intracellular inhibitory domain of PD1 with a 4-1BB co-stimulatory domain, and CAR-T cells containing this signal transduction molecule. The signal transduction molecule of this invention can convert the immunosuppressive signal of PD1 / PD-L1 into a T-cell activating signal, enhancing the tumor-killing ability of CAR-T cells and showing promise for application in the field of anti-tumor therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedicine. Specifically, this invention relates to PD1-based signal transduction molecules, CAR-T cells, and their applications. Background Technology

[0002] Chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved great success in the treatment of B-cell malignancies, with several CAR-T products targeting the CD19 antigen already approved for marketing. Currently, the second-generation CAR-T structure is widely used clinically, consisting of an extracellular binding domain, a hinge region, a transmembrane domain, and an intracellular signaling domain. The intracellular signaling domain includes a co-stimulatory domain and an intracellular domain of CD3ζ. Commonly used co-stimulatory molecules are CD28 and 4-1BB. CAR-T cells prepared using different co-stimulatory molecules exhibit different biochemical characteristics. CAR-T cells containing the CD28 co-stimulatory molecule show high initial activation intensity and high cytokine secretion, but poor persistence, easily leading to T cell exhaustion. CAR-T cells containing the 4-1BB co-stimulatory molecule, while exhibiting better persistence, have lower initial activation levels and slightly lower cytokine secretion.

[0003] PD1 / PD-L1 are a key pair of molecules in immunotherapy. After T cells are activated, they highly express PD1 on their surface. PD1, as a marker of T cell exhaustion, itself affects T cell function. Meanwhile, tumor cells have evolved the ability to resist the body's immune system over a long period of evolution. Some tumor cells highly express PD-L1, while others express PD-L1 after treatment with specific stimuli such as IFNγ. The binding of PD1 and PD-L1 further inhibits T cell function, leading to T cell dysfunction and helping tumor cells evade immune surveillance, ultimately resulting in immune escape.

[0004] Therefore, there is a need in the field to develop CAR-T cells that can mitigate or prevent immune escape and simultaneously possess strong effector function and persistence. Summary of the Invention

[0005] The purpose of this invention is to provide CAR-T cells that can reduce or prevent immune escape and simultaneously possess strong effector function and persistence.

[0006] In a first aspect of the invention, a signal conversion molecule is provided, the signal conversion molecule comprising:

[0007] i) Extracellular domains of the PD1 molecule;

[0008] ii) Hinge region and transmembrane region; and

[0009] iii) Intracellular co-stimulatory domain derived from 41BB.

[0010] In another preferred embodiment, the extracellular domain amino acid sequence of the PD1 molecule is shown in SEQ ID NO:2.

[0011] In another preferred embodiment, the signal transduction molecule further includes a CD3ζ-derived cytoplasmic signal transduction sequence located at the C-terminus.

[0012] In another preferred embodiment, the signal conversion molecule has the structure shown in Formula I:

[0013] PT-IC-CD3ζ(I)

[0014] In the formula,

[0015] Each "-" independently represents a linking peptide or peptide bond;

[0016] P is the extracellular domain of the PD1 molecule;

[0017] T represents the hinge region and the transmembrane region;

[0018] IC is an intracellular co-stimulatory domain;

[0019] CD3ζ is a cytoplasmic signaling sequence that is absent or derived from CD3ζ.

[0020] In another preferred embodiment, the hinge region and transmembrane region are derived from proteins selected from the group consisting of CD8α, CD28, CD3epsilon, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or combinations thereof.

[0021] In another preferred embodiment, the amino acid sequences of the hinge region and transmembrane region are as shown in SEQ ID NO:4.

[0022] In another preferred embodiment, the intracellular co-stimulatory domain is an intracellular co-stimulatory domain derived from 4-1BB.

[0023] In another preferred embodiment, the intracellular co-stimulatory domain amino acid sequence is shown in SEQ ID NO:7.

[0024] In another preferred embodiment, the amino acid sequence of the signal conversion molecule is shown in SEQ ID NO:9.

[0025] In a second aspect of the invention, a nucleic acid molecule is provided, the nucleic acid molecule comprising a polynucleotide encoding a signal transduction molecule as described in the first aspect of the invention.

[0026] In another preferred embodiment, the polynucleotide sequence is as shown in SEQ ID NO:8.

[0027] In another preferred embodiment, the nucleic acid molecule further comprises a polynucleotide encoding a chimeric antigen receptor (CAR).

[0028] In another preferred embodiment, the chimeric antigen receptor targets B7-H3.

[0029] In another preferred embodiment, the chimeric antigen receptor comprises an extracellular antigen-binding domain, a transmembrane region, an intracellular co-stimulatory domain, and a cytoplasmic signal transduction sequence derived from CD3ζ.

[0030] In another preferred embodiment, the signal transducer molecule and the CAR have intracellular co-stimulatory domains derived from different proteins.

[0031] In another preferred embodiment, the signal transducer molecule has an intracellular co-stimulatory domain derived from 4-1BB, and the CAR has an intracellular co-stimulatory domain derived from CD28.

[0032] In another preferred embodiment, the CAR has the structure shown in Formula II:

[0033] EB-MH-TM-C-CD3ζ (II)

[0034] In the formula,

[0035] Each "-" independently represents a linking peptide or peptide bond;

[0036] EB is an extracellular binding domain;

[0037] H represents the region without hinges;

[0038] TM stands for transmembrane region;

[0039] C is the intracellular co-stimulatory domain;

[0040] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ.

[0041] In another preferred embodiment, the extracellular binding domain of the CAR is an antigen-binding fragment (scFv) that specifically binds to B7-H3.

[0042] In another preferred embodiment, the extracellular binding domain EB sequence of the CAR is shown in SEQ ID NO:10.

[0043] In another preferred embodiment, H is a hinge region of a protein selected from the group consisting of CD8α, CD28, CD137, or combinations thereof.

[0044] In another preferred embodiment, H is a hinge region derived from CD8α.

[0045] In another preferred embodiment, the TM is a transmembrane region of a protein selected from the group consisting of: CD28, CD3epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or a combination thereof.

[0046] In another preferred embodiment, the TM is a transmembrane region derived from CD8α.

[0047] In another preferred embodiment, the amino acid sequences of the hinge region and the transmembrane region are as shown in SEQ ID NO:4.

[0048] In another preferred embodiment, in the nucleic acid molecule, the polynucleotide encoding the signal conversion molecule and the polynucleotide encoding CAR are tandemly linked by a self-splicing sequence.

[0049] In another preferred embodiment, the self-cutting sequence is a T2A or P2A sequence.

[0050] In another preferred embodiment, the DNA sequence encoding the self-cleaving sequence is shown in SEQ ID NO:11.

[0051] In a third aspect of the invention, a carrier is provided, said carrier containing nucleic acid molecules as described in the second aspect of the invention.

[0052] In another preferred embodiment, the vector is selected from the group consisting of DNA, RNA, plasmids, lentiviral vectors, adenovirus vectors, retroviral vectors, transposons, or combinations thereof.

[0053] In another preferred embodiment, the vector is a lentiviral vector.

[0054] In another preferred embodiment, the vector further includes a selection from the group consisting of: promoters, transcriptional enhancement elements (WPREs), long terminal repeat sequences (LTRs), etc.

[0055] In a fourth aspect of the invention, an engineered immune cell is provided, the immune cell containing a vector or chromosome as described in the third aspect of the invention, or expressing a signal transduction molecule as described in the first aspect of the invention.

[0056] In another preferred embodiment, the engineered immune cells are selected from the group consisting of T cells, NK cells, NKT cells, macrophages, or combinations thereof.

[0057] In another preferred embodiment, the engineered immune cells are chimeric antigen receptor T cells (CAR-T cells) or chimeric antigen receptor NK cells (CAR-NK cells).

[0058] In another preferred embodiment, the engineered immune cell is a CAR-T cell.

[0059] In another preferred embodiment, the engineered immune cells express the signal transducer molecule and the chimeric antigen receptor.

[0060] In another preferred embodiment, the chimeric antigen receptor targets B7-H3.

[0061] In another preferred embodiment, the chimeric antigen receptor comprises an extracellular antigen-binding domain, a transmembrane region, an intracellular co-stimulatory domain, and a cytoplasmic signal transduction sequence derived from CD3ζ.

[0062] In another preferred embodiment, the signal transducer molecule and the CAR have intracellular co-stimulatory domains derived from different proteins.

[0063] In another preferred embodiment, the signal transducer molecule has an intracellular co-stimulatory domain derived from 4-1BB, and the CAR has an intracellular co-stimulatory domain derived from CD28.

[0064] In another preferred embodiment, the CAR has the structure shown in Formula II:

[0065] EB-MH-TM-C-CD3ζ(II)

[0066] In the formula,

[0067] Each "-" independently represents a linking peptide or peptide bond;

[0068] EB is an extracellular binding domain;

[0069] H represents the region without hinges;

[0070] TM stands for transmembrane region;

[0071] C is the intracellular co-stimulatory domain;

[0072] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ.

[0073] In another preferred embodiment, the extracellular binding domain of the CAR is an antigen-binding fragment (scFv) that specifically binds to B7-H3.

[0074] In another preferred embodiment, the extracellular binding domain EB sequence of the CAR is shown in SEQ ID NO:10.

[0075] In another preferred embodiment, H is a hinge region of a protein selected from the group consisting of CD8α, CD28, CD137, or combinations thereof.

[0076] In another preferred embodiment, H is a hinge region derived from CD8α.

[0077] In another preferred embodiment, the TM is a transmembrane region of a protein selected from the group consisting of: CD28, CD3epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, or a combination thereof.

[0078] In another preferred embodiment, the TM is a transmembrane region derived from CD8α.

[0079] In another preferred embodiment, the amino acid sequences of the hinge region and the transmembrane region are as shown in SEQ ID NO:4.

[0080] In another preferred embodiment, in the nucleic acid molecule, the polynucleotide encoding the signal conversion molecule and the polynucleotide encoding CAR are tandemly linked by a self-splicing sequence.

[0081] In another preferred embodiment, the self-cutting sequence is a T2A or P2A sequence.

[0082] In another preferred embodiment, the amino acid sequence of the self-cleaving sequence is shown in SEQ ID NO:11.

[0083] In a fifth aspect of the present invention, a method for preparing engineered immune cells as described in the fourth aspect of the present invention is provided, comprising the steps of: transducing a nucleic acid molecule as described in the second aspect of the present invention or a vector as described in the third aspect of the present invention into immune cells, thereby obtaining the engineered immune cells.

[0084] In another preferred embodiment, the method further includes a step of testing the function and effectiveness of the obtained engineered immune cells.

[0085] In a sixth aspect of the invention, a pharmaceutical composition is provided, the pharmaceutical composition comprising a nucleic acid molecule as described in the second aspect of the invention, a carrier as described in the third aspect of the invention, and / or engineered immune cells as described in the fourth aspect of the invention, as well as a pharmaceutically acceptable carrier, diluent, or excipient.

[0086] In another preferred embodiment, the formulation is a liquid formulation.

[0087] In another preferred embodiment, the dosage form of the preparation is an injection.

[0088] In another preferred embodiment, the concentration of the engineered immune cells in the formulation is 1 × 10⁻⁶. 3- 1×10 8 Cells / ml, preferably 1×10⁻⁶ 4 -1×10 7 Cells / ml

[0089] In a seventh aspect of the invention, there is provided the use of a nucleic acid molecule as described in the second aspect of the invention, a carrier as described in the third aspect of the invention, and / or engineered immune cells as described in the fourth aspect of the invention, and / or a pharmaceutical composition as described in the sixth aspect of the invention, for the preparation of a medicament or formulation for the prevention and / or treatment of a disease.

[0090] In another preferred embodiment, the disease is a PD-L1 positive tumor.

[0091] In another preferred embodiment, the tumor is selected from the group consisting of solid tumors, hematomas, or combinations thereof.

[0092] In another preferred embodiment, the solid tumor is selected from the group consisting of: gastric cancer, peritoneal metastasis of gastric cancer, liver cancer, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, cervical cancer, ovarian cancer, lymphoma, nasopharyngeal carcinoma, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC), glioma, endometrial cancer, or combinations thereof.

[0093] In another preferred embodiment, the hematologic malignancy is selected from the group consisting of: acute myeloid leukemia (AML), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma, or combinations thereof.

[0094] In another preferred embodiment, the tumor is breast cancer.

[0095] In an eighth aspect of the invention, a method for treating a disease is provided, comprising administering to a subject requiring treatment an effective amount of engineered immune cells as described in the fourth aspect of the invention, or a pharmaceutical composition as described in the sixth aspect of the invention.

[0096] In another preferred embodiment, the disease is a PD-L1 positive tumor.

[0097] In another preferred embodiment, the CAR immune cells contained in the engineered immune cells or pharmaceutical composition are cells derived from the subject (autologous cells).

[0098] In another preferred embodiment, the CAR immune cells contained in the engineered immune cells or pharmaceutical composition are cells derived from a healthy individual (allogeneic cells).

[0099] In another preferred embodiment, the method may be used in combination with other treatment methods.

[0100] In another preferred embodiment, the other treatment methods include chemotherapy, radiotherapy, targeted therapy, etc.

[0101] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0102] The following figures are used to illustrate specific embodiments of the present invention and are not intended to limit the scope of the invention as defined by the claims.

[0103] Figure 1 The structural diagrams of B7-H3-28ζ-CAR and B7-H3-28ζ-PD1-BB-CAR and their T-cell infection efficiency are shown. (A) Structural diagrams of B7-H3-28ζ-CAR and B7-H3-28ζ-PD1-BB-CAR, where scFv.376.96 is the variable region sequence of antibody 376.96 targeting B7-H3, CD8α: hinge region and transmembrane domain of CD8α, CD28: intracellular co-stimulatory domain of CD28, CD3ζ: intracellular domain of CD3ζ, 2A: self-splicing peptide sequence, PD1: extracellular domain of PD1, F: Flag tag, 4-1BB: intracellular co-stimulatory domain of 4-1BB. (B) Representative flow cytometry plots of the expression efficiency of B7-H3-28ζ-CAR and B7-H3-28ζ-PD1-BB-CAR on the surface of T cells. (C) Summary of expression efficiency of B7-H3-28ζ-CAR and B7-H3-28ζ-PD1-BB-CAR on the surface of multiple donor T cells, n=7.

[0104] Figure 2 The expression levels of B7-H3 and PD-L1 in MB231 and MB231-PD-L1 cells are shown. (A) Expression level of B7-H3 in MB231 and MB231-PD-L1 cells. (B) Expression level of PD-L1 in MB231 and MB231-PD-L1 cells.

[0105] Figure 3 The results show that B7-H3-28ζ-PD1-BB-CAR-T cells exhibited a sustained ability to eliminate tumor cells in multiple rounds of co-culture experiments. (A) Flowchart of multiple rounds of co-culture. Tumor cells were seeded into 24-well plates one day in advance. CAR-T cells were added on day 0, with a T cell to tumor cell ratio of 1:5. Each round of co-culture was performed in duplicate. On days 4, 7, 11, 14, and 17, half of the T cells from one well of the previous round of co-culture were collected and added to the tumor cells seeded one day in advance. All cells in the other well were collected, and T cell (CD3+) levels were analyzed by flow cytometry. + ) and tumor cells (GFP) + (B) Quantity. Representative flow cytometry plots of multiple co-cultures.

[0106] Figure 4 The table shows a summary of T cell counts from multiple rounds of co-culture experiments.

[0107] Figure 5 The results show a summary of tumor cell counts from multiple rounds of co-culture experiments.

[0108] Figure 6 This presents a summary of IFN-γ secreted during multiple rounds of co-culture experiments.

[0109] Figure 7 This shows a summary of IL-2 secreted during multiple rounds of co-culture experiments.

[0110] Figure 8 This diagram shows that CAR-T cells carrying PD1-BB exhibit superior anti-tumor effects in a breast cancer metastasis model. (A) Flowchart evaluating the efficacy of CAR-T cell tumor therapy by constructing a metastasis model in NCG mice using breast cancer cells MDA-MB-231-PD-L1. (B) Representative bioluminescence graph of tumor growth in the MDA-MB-231-PD-L1 metastasis model. (C) Tumor cell growth was detected using IVIS mouse in vivo imaging, with weekly monitoring and recording of changes in Luciferase fluorescence values ​​for each mouse. (D) Survival curves of the MDA-MB-231-PD-L1 metastasis model mice.

[0111] Figure 9 The diagrams show the structural schematics of CARs, T cell infection efficiency, and CAR-T cell proliferation. (A) Structural schematics of PD1-BB-CAR, PD1-BBζ-CAR, B7H3-28ζ-CAR, and B7H3-28ζ-PD1-BB-CAR. (B) Representative flow cytometry results of CAR expression, detected using antibodies recognizing B7H3-scFv and Flag, respectively. (C) Summary results of multiple experiments on CAR expression efficiency, n=3. (D) Summary results of multiple experiments on CAR amplification curves, n=3.

[0112] Figure 10 This demonstrates that the PD1-BB receptor can mediate the killing of PD-L1-positive tumor cells by sharing CD3ζ with CARs. (AB) Flow cytometry representations of B7-H3 (A) and PD-L1 (B) expression levels in wild-type and PD-L1-overexpressing MDA-MB-453 tumor cells. (C) Representative flow cytometry representations of CAR-T cells co-cultured with wild-type and PD-L1-overexpressing MDA-MB-453 cells for 5 days. Detailed Implementation

[0113] Through extensive and in-depth research, the inventors have developed for the first time a PD1-based signal transduction molecule, CAR-T cells, and their applications. This invention designs a special signal transduction molecule that replaces the intracellular inhibitory domain of PD1 with a 4-1BB co-stimulatory domain, constructing B7-H3-28ζ-CAR-T cells carrying a PD1-BB chimeric receptor. When T cells bind to tumor cells, they can convert the immunosuppressive signal of PD1 / PD-L1 into a T cell activating signal. Simultaneously, by combining the advantages of the CD28 co-stimulatory molecule, the tumor-killing ability of CAR-T cells is further enhanced, and their in vivo survival time is prolonged. Based on this, the invention was completed.

[0114] the term

[0115] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. As used herein, when referring to a specifically enumerated numerical value, the term “about” means that the value can vary from the enumerated value by no more than 1%. For example, as used herein, the expression “about 100” includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0116] As used herein, the terms “optional” or “optionally” mean that the events or circumstances described below may occur but are not required to occur.

[0117] As used herein, the terms “containing” or “including (comprise)” can be open-ended, semi-closed, or closed. In other words, the terms also include “consistently made of” or “composed of”.

[0118] "Transduction," "transfection," "conversion," or the terms used herein refer to the process of delivering exogenous polynucleotides to host cells, where they are transcribed and translated to produce polypeptide products, including the introduction of exogenous polynucleotides into host cells (e.g., E. coli) using plasmid molecules.

[0119] "Gene expression" or "expression" refers to the process by which genes are transcribed, translated, and modified post-translationally to produce their RNA or protein products.

[0120] "Polynucleotide" refers to a polymer of nucleotides of any length, including deoxyribonucleotides (DNA), ribonucleotides (RNA), their hybrid sequences, and analogs. Polynucleotides may include modified nucleotides, such as methylated or capped nucleotides or nucleotide analogs. As used herein, the term polynucleotide refers to interchangeable single-stranded and double-stranded molecules. Unless otherwise stated, polynucleotides in any embodiment described herein include double-stranded forms and two complementary single strands that constitute a double-stranded form, as known or predictable.

[0121] Substitution of conserved amino acids is known in the art. In some embodiments, potential substituted amino acids are in one or more of the following group: glycine, alanine; and valine, isoleucine, leucine, and proline; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine, lysine, arginine, and histidine; and / or phenylalanine, tryptophan, and tyrosine; methionine and cysteine. Furthermore, the present invention also provides non-conserved amino acid substitutions that allow for substitution of amino acids from different groups.

[0122] The term “about” can refer to a value or composition within an acceptable range of error for a particular value or composition as determined by a person skilled in the art, which will depend in part on how the value or composition is measured or determined.

[0123] The term “giving” means the physical introduction of the product of the present invention into a subject using any of the various methods and delivery systems known to those skilled in the art, including intravenous, intramuscular, subcutaneous, intraperitoneal, spinal, or other parenteral routes of administration, such as by injection or infusion.

[0124] The signal conversion molecule of the present invention

[0125] As used herein, the terms “signal-converting molecule,” “signal-converting molecule of the present invention,” “PD1-BB chimeric receptor,” and “PD1-4-1BB” all refer to the signal-converting molecule provided in the first aspect of the present invention.

[0126] The signal transduction molecule of this invention comprises an extracellular domain, a transmembrane region, and an intracellular co-stimulatory domain of the PD1 molecule. This invention converts the inhibitory signal of PD1 / PD-L1 into a T cell activating signal by coupling the extracellular region of PD1 with a co-stimulatory molecule. The intracellular co-stimulatory domain used in the signal transduction molecule of this invention can be derived from 4-1BB, CD28, or a combination thereof. In one embodiment, the intracellular co-stimulatory domain is a 4-1BB co-stimulatory molecule.

[0127] In some embodiments, the signal transduction molecule of the present invention may further include a C-terminal CD3ζ region (a cytoplasmic signaling sequence derived from CD3ζ) to achieve T cell activation. In other embodiments, the signal transduction molecule of the present invention can be expressed on the surface of chimeric antigen receptor (CAR) immune cells, achieving T cell activation by sharing the CD3ζ region with the CAR.

[0128] When expressed on the surface of chimeric antigen receptor (CAR) immune cells, the signal transduction molecule of the present invention may have the same or different intracellular co-stimulatory domains as the CAR molecule. In a preferred embodiment, the signal transduction molecule of the present invention has different intracellular co-stimulatory domains from the CAR molecule. For example, they may each have intracellular co-stimulatory domains derived from 4-1BB and CD28, respectively. When CD28 is used as the co-stimulatory molecule, CAR-T immune cells bind to tumor cells, resulting in faster activation, higher activation intensity, higher initial tumor-killing activity, and secretion of more cytokines. However, this also leads to a greater likelihood of CAR-T cell exhaustion, thus limiting their proliferative capacity and resulting in poorer long-term survival. Conversely, when 4-1BB is used as the co-stimulatory molecule, the initial activation intensity of CAR-T cells is milder, the activation rate is slightly slower, the tumor cell killing rate is also slightly slower, and the amount of cytokine secreted is slightly lower. However, the proliferative capacity after activation is stronger, and a larger proportion of CAR-T cells differentiate into memory T cells, resulting in better persistence and stronger long-term survival. This invention utilizes signal-switching molecules and CARs carrying CD28 and 4-1BB co-stimulatory molecules respectively to integrate signals, enabling CAR-T to obtain the optimal activation signal while ensuring killing intensity and persistence.

[0129] In this invention, the signal transduction molecule of this invention also includes a sequence-based conserved variant, which means that compared with the amino acid sequence of SEQ ID NO:9, up to 30, preferably up to 20, more preferably up to 10, and most preferably up to 5 amino acids are replaced by amino acids with similar or analogous properties to form a polypeptide.

[0130] Chimeric antigen receptor

[0131] The signal transduction molecules of this invention can be expressed on the surface of chimeric antigen receptor immune cells. The chimeric immunoantigen receptor includes an extracellular antigen recognition region, a transmembrane region, and an intracellular co-stimulatory signaling region.

[0132] The extracellular domain includes a target-specific binding element. This extracellular domain can be an antibody scFv based on antigen-antibody specific binding, or a natural sequence or derivative thereof based on ligand-receptor specific binding. In this invention, the extracellular binding domain of the chimeric antigen receptor can specifically bind to the following antigens: B7-H3, EGFRvIII, IL13Rα2, Mesothelin, Mucin-1, CEA, HER2, CLDN18.2, PSMA, GD, PSMA2, CD19, BCMA, CD20, CD22, CXCR5, CD38, or combinations thereof, but is not limited thereto.

[0133] Intracellular domains include the costimulatory signaling region and the ζ-chain portion. The costimulatory signaling region refers to a portion of the intracellular domain that includes costimulatory molecules. Costimulatory molecules are cell surface molecules required for an effective lymphocyte response to antigens, not antigen receptors or their ligands.

[0134] A linker may be incorporated between the extracellular and transmembrane domains of the CAR, or between the cytoplasmic and transmembrane domains of the CAR. As used herein, the term "linker" generally refers to any oligopeptide or polypeptide that functions to link the transmembrane domain to the extracellular or cytoplasmic domain of the polypeptide chain. Linkers may comprise 0-300 amino acids, preferably 2 to 100 amino acids, and most preferably 3 to 50 amino acids.

[0135] When expressed in T cells, CARs can recognize antigens based on antigen-binding specificity. When they bind to their associated antigens, they affect tumor cells, causing them to stop growing, die, or otherwise be affected, leading to a reduction or elimination of the patient's tumor burden. The antigen-binding domain is preferably fused with one or more intracellular domains derived from co-stimulatory molecules and the ζ chain. Preferably, the antigen-binding domain is fused with an intracellular domain combining the CD8α hinge region, the CD8α transmembrane region, the CD28 co-stimulatory domain, and the CD3ζ signaling domain.

[0136] For the hinge region and transmembrane region (transmembrane domain), the CAR can be designed to include a transmembrane domain fused to the extracellular domain of the CAR. In one implementation, a transmembrane domain naturally associated with one of the domains in the CAR is used. In some examples, the transmembrane domain can be selected, or modified by amino acid substitution, to avoid binding such a domain to the transmembrane domain of the same or different surface membrane proteins, thereby minimizing interactions with other members of the receptor complex.

[0137] In one embodiment of the present invention, the intracellular domains in the CAR include the CD28 co-stimulatory domain and the CD3ζ signal transduction domain.

[0138] In one embodiment of the present invention, the CAR is a CAR that can specifically target B7-H3.

[0139] Chimeric antigen receptor immune cells (CAR-immune cells)

[0140] In this invention, a chimeric antigen receptor immune cell is provided, which contains the signal transduction molecule of this invention.

[0141] The chimeric antigen receptor immune cells of the present invention can be CAR-T cells, CAR-NK cells, or CAR-macrophages. Preferably, the chimeric antigen receptor immune cells of the present invention are CAR-T cells.

[0142] As used herein, the terms "CAR-T cell", "CAR-T", and "CAR-T cell of the present invention" all refer to the CAR-T cell described in the fourth aspect of the present invention.

[0143] CAR-T cells have the following advantages over other T-cell-based therapies: (1) The action of CAR-T cells is not limited by MHC; (2) Given that many tumor cells express the same tumor markers, once the CAR gene targeting a certain tumor marker is constructed, it can be widely used; (3) CAR can utilize both tumor protein markers and glycolipid non-protein markers, thus expanding the target range of tumor markers; (4) Using the patient's own cells reduces the risk of rejection; (5) CAR-T cells have immune memory function and can survive in the body for a long time.

[0144] As used herein, the terms "CAR-NK cell," "CAR-NK," and "CAR-NK cell of the present invention" all refer to the CAR-NK cell described in the fourth aspect of the present invention. The CAR-NK cell of the present invention can be used to treat tumors.

[0145] Natural killer (NK) cells are a major type of immune effector cells that protect the body from viral infections and tumor cell invasion through non-antigen-specific pathways. Engineered (genetically modified) NK cells may acquire new functions, including the ability to specifically recognize tumor antigens and enhanced anti-tumor cytotoxicity.

[0146] Compared with CAR-T cells, CAR-NK cells have the following advantages, such as: (1) they directly kill tumor cells by releasing perforin and granzymes, without killing normal cells in the body; (2) they release very little cytokine, thus reducing the risk of cytokine storm; and (3) they are very easy to expand in vitro and develop into "ready-made" products. Otherwise, they are similar to CAR-T cell therapy.

[0147] carrier

[0148] The nucleic acid sequence encoding the desired molecule can be obtained using recombination methods known in the art, such as, for example, by screening a library from a cell expressing the gene, by obtaining the gene from a vector known to contain the gene, or by directly isolating the gene from cells and tissues containing the gene using standard techniques. Optionally, the gene of interest can be synthesized.

[0149] This invention provides polynucleotides encoding signal transducers and CARs, which can be expressed in the same expression cassette or separately in different expression cassettes. In a preferred embodiment, the polynucleotides encoding signal transducers and CARs can be constructed in a tandem configuration and expressed in the same expression cassette. The nucleic acid sequences of the nucleic acid molecules encoding signal transducers and CARs can be linked by any self-splicing sequence, preferably by a T2A sequence.

[0150] This invention also provides vectors comprising the nucleic acid molecules of this invention. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for achieving long-term gene transfer because they allow for long-term, stable integration of transgenes and their proliferation in daughter cells. Lentiviral vectors have advantages over vectors derived from oncogenic retroviruses, such as murine leukemia viruses, because they can transduce non-proliferating cells, such as hepatocytes. They also have the advantage of low immunogenicity.

[0151] In short, the expression cassette or nucleic acid sequence of this invention is typically operatively linked to a promoter and incorporated into an expression vector. This vector is suitable for replication and integration into eukaryotic cells. A typical cloning vector contains transcription and translation terminators, an initial sequence, and a promoter that can be used to regulate the expression of the desired nucleic acid sequence.

[0152] The expression constructs of the present invention can also be used with standard gene delivery protocols for nucleic acid immunotherapy and gene therapy. Methods of gene delivery are known in the art. See, for example, U.S. Patent Nos. 5,399,346, 5,580,859, and 5,589,466, which are incorporated herein by reference in their entirety. In another embodiment, the present invention provides a gene therapy vector.

[0153] This nucleic acid can be cloned into many types of vectors. For example, it can be cloned into vectors including, but not limited to, plasmids, phage particles, phage derivatives, animal viruses, and granules. Specific vectors of interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.

[0154] Furthermore, the expression vector can be provided to cells in the form of a viral vector. Viral vector technology is well known in the art and has been described, for example, in Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, ColdSpring Harbor Laboratory, New York) and other virology and molecular biology manuals. Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpesviruses, and lentiviruses. Typically, a suitable vector contains at least one origin of replication functioning in an organism, a promoter sequence, a convenient restriction enzyme site, and one or more optional markers (e.g., WO01 / 96584; WO01 / 29058; and U.S. Patent No. 6,326,193).

[0155] Many virus-based systems have been developed for transferring genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. Selected genes can be inserted into vectors and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to target cells in vivo or in vitro. Many retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art. In one embodiment, lentiviral vectors are used.

[0156] Additional promoter elements, such as enhancers, can regulate the frequency of transcription initiation. These are typically located in a 30–110 bp region upstream of the start site, although recent studies have shown that many promoters also contain functional elements downstream of the start site. The spacing between promoter elements is often flexible to maintain promoter function when an element is inverted or moved relative to another. In the thymidine kinase (TK) promoter, the spacing between promoter elements can be increased to 50 bp before activity begins to decline. Depending on the promoter, individual elements can function cooperatively or independently to initiate transcription.

[0157] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strongly constitutive promoter sequence capable of driving high-level expression of any polynucleotide sequence operatively linked thereto. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to the early promoter of simian virus 40 (SV40), mouse mammary cancer virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr virus immediate early promoter, Russ's sarcoma virus promoter, and human gene promoters, such as, but not limited to, actin promoter, myosin promoter, heme promoter, and creatine kinase promoter. Furthermore, the invention should not be limited to the application of constitutive promoters. Inducible promoters are also considered as part of the invention. The use of inducible promoters provides a molecular switch that can turn on the expression of a polynucleotide sequence operatively linked to the inducible promoter when such expression is desired, or turn off expression when expression is undesirable. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.

[0158] To assess the expression of CAR peptides or portions thereof, the expression vector introduced into cells may also contain either or both of an optional marker gene or a reporter gene to facilitate the identification and selection of expressing cells from a population of cells seeking transfection or infection via a viral vector. Alternatively, the optional marker may be carried on a separate DNA segment and used in co-transfection procedures. Both the optional marker and the reporter gene may be flanked by appropriate regulatory sequences to enable expression in host cells. Useful optional markers include, for example, antibiotic resistance genes such as neo.

[0159] Reporter genes are used to identify potentially transfected cells and to evaluate the functionality of regulatory sequences. Typically, a reporter gene is a gene that is not present in or is expressed by the recipient organism or tissue, and that encodes a polypeptide whose expression is clearly indicated by readily detectable properties such as enzyme activity. The expression of the reporter gene is determined at an appropriate time after DNA has been introduced into the recipient cells. Suitable reporter genes may include genes encoding luciferase, β-galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase, or green fluorescent protein (e.g., Ui-Tei et al., 2000 FEBS Letters 479:79-82). In one embodiment of the invention, the reporter gene is a gene encoding mKate2 red fluorescent protein. Suitable expression systems are well known and can be prepared using known techniques or are commercially available. Typically, a construct exhibiting the highest level of reporter gene expression with at least five flanking regions is identified as a promoter. Such promoter regions can be ligated into reporter genes and used to evaluate the ability of reagents to regulate promoter-driven transcription.

[0160] Methods for introducing genes into cells and expressing genes into cells are known in the art. Within the scope of expression vectors, the vector can be readily introduced into host cells, such as mammalian, bacterial, yeast, or insect cells, by any method in the art. For example, expression vectors can be transferred into host cells by physical, chemical, or biological means.

[0161] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipid transfection, particle bombardment, microinjection, electroporation, and so on. Methods for producing cells comprising vectors and / or exogenous nucleic acids are well known in the art. See, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). A preferred method for introducing polynucleotides into host cells is calcium phosphate transfection.

[0162] Biological approaches to introducing polynucleotides of interest into host cells include the use of DNA and RNA vectors. Viral vectors, particularly retroviral vectors, have become the most widely used method for inserting genes into mammalian cells, such as human cells. Other viral vectors may be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, among others. See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.

[0163] Chemical means of introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, and beads; and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system used as a delivery vehicle in both in vitro and in vivo is the liposome (e.g., an artificial membrane capsule).

[0164] In the case of using a non-viral delivery system, an exemplary delivery tool is a liposome. Consider using a lipid formulation to introduce nucleic acid into host cells (in vitro, ex vivo, or in vivo). Alternatively, the nucleic acid may be associated with a lipid. Lipid-associated nucleic acid can be encapsulated within the aqueous interior of a liposome, dispersed within the lipid bilayer of the liposome, attached to the liposome via a linker molecule associated with both the liposome and the oligonucleotide, trapped within the liposome, complexed with the liposome, dispersed in a solution containing lipids, mixed with lipids, conjugated with lipids, contained in lipids as a suspension, contained in or complexed with micelles, or otherwise associated with lipids. The lipids, lipid / DNA, or lipid / expression vector associated with the composition are not limited to any specific structure in solution. For example, they may be present in a bilayer structure, as micelles, or have a “collapsed” structure. They may also be simply dispersed in solution, possibly forming aggregates of varying sizes or shapes. Lipids are fatty substances and can be naturally occurring or synthetic lipids. For example, lipids include fat droplets, which occur naturally in the cytoplasm and in compounds containing long-chain aliphatic hydrocarbons and their derivatives such as fatty acids, alcohols, amines, amino alcohols and aldehydes.

[0165] In a preferred embodiment of the present invention, the vector is a retroviral vector.

[0166] preparation

[0167] This invention provides a formulation comprising the signal transducer described in the first aspect of this invention, the nucleic acid molecule described in the second aspect of this invention, the carrier described in the third aspect of this invention, or the engineered immune cells described in the fourth aspect of this invention, and a pharmaceutically acceptable carrier, diluent, or excipient. In one embodiment, the formulation is a liquid formulation. Preferably, the formulation is an injectable formulation. Preferably, the concentration of the CAR-T cells in the formulation is 1 × 10⁻⁶. 3 -1×10 8 Cells / ml, more optimal 1×10 4 -1×10 7 Cells / ml

[0168] In one embodiment, the formulation may include buffer solutions such as neutral buffered saline, sulfate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose, or dextran, mannitol; proteins; peptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The formulations of the present invention are preferably formulated for intravenous administration.

[0169] Therapeutic applications

[0170] This invention includes therapeutic applications using immune cells (e.g., T cells) expressing the signal transduction molecules of this invention. It can target tumor cell markers, synergistically activate T cells, elicit an immune response from immune cells, thereby significantly improving their efficiency in killing tumor cells.

[0171] Therefore, the present invention also provides a method for stimulating a T-cell-mediated immune response against a target cell population or tissue in mammals, comprising the step of administering the CAR-cells of the present invention to a mammal.

[0172] In one embodiment, the present invention includes a type of cell therapy in which the patient's own T cells (or those from a heterologous donor) are isolated, activated, and genetically modified to produce CAR-T cells, which are then injected into the same patient. This method results in an extremely low probability of graft-versus-host disease, and the antigen is recognized by the T cells in an MHC-free manner. Furthermore, a single CAR-T cell can treat all cancers expressing that antigen. Unlike antibody therapy, CAR-T cells can replicate in vivo, producing long-lasting, durable antibodies that lead to sustained tumor control.

[0173] In one embodiment, the CAR-T cells of the present invention can undergo robust in vivo T cell expansion and sustain for an extended period of time. Additionally, the CAR-mediated immune response can be part of an adoptive immunotherapy step, wherein CAR-modified T cells induce an immune response specific to the antigen-binding domain in the CAR. For example, anti-B7-H3 CAR-T cells elicit a specific immune response targeting B7-H3 cells.

[0174] Although the data disclosed herein specifically discloses retroviral vectors comprising a combination of anti-B7-H3 scFv, hinge and transmembrane regions, and CD28 co-stimulatory domains and CD3ζ signaling domains, the present invention should be construed as including any number of variations in each of the construct components.

[0175] Treatable cancers include tumors that are not vascularized or are substantially not vascularized, as well as vascularized tumors. Cancers include non-solid tumors (such as hematologic malignancies, such as leukemia and lymphoma) and solid tumors. Types of cancers treatable with the CAR of this invention include, but are not limited to, carcinomas, germ cell tumors, and sarcomas, and certain leukemias or lymphomas, benign and malignant tumors, and malignant tumors such as sarcomas, carcinomas, and melanomas. Adult tumors / cancers and childhood tumors / cancers are also included.

[0176] Hematologic cancers are cancers of the blood or bone marrow. Examples of hematologic (or blood-borne) cancers include leukemia, including acute leukemia (such as acute lymphoblastic leukemia, acute myeloid leukemia, acute myeloid leukemia, and myeloblastic, promyelocytic, granulocytic, monocytic, and erythroleukemia), chronic leukemia (such as chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (painless and high-grade forms), multiple myeloma, Waldenström's macroglobulinemia, heavy chain disease, myelodysplastic syndromes, hairy cell leukemia, and spinal dysplasia.

[0177] The CAR-modified T cells of the present invention can also be used as a type of vaccine for in vitro immunization and / or in vivo therapy in mammals. Preferably, the mammal is human.

[0178] For in vitro immunization, at least one of the following occurs in vitro before the cells are administered into a mammal: i) cell expansion, ii) introduction of nucleic acid encoding CAR into the cells, and / or iii) cryopreservation of the cells.

[0179] In vitro procedures are well known in the art and are discussed more fully below. Simply put, cells are isolated from a mammal (preferably human) and genetically modified (i.e., transduced or transfected in vitro) using a vector expressing a CAR disclosed herein. The CAR-modified cells can be administered to a mammalian recipient to provide therapeutic benefit. The mammalian recipient can be human, and the CAR-modified cells can be autologous relative to the recipient. Alternatively, the cells can be allogeneic, syngeneic, or xenogeneic relative to the recipient.

[0180] In addition to using cell-based vaccines for ex vivo immunization, the present invention also provides compositions and methods for in vivo immunization to elicit an immune response against antigens in a patient.

[0181] The present invention provides a method for treating tumors, comprising administering a therapeutically effective amount of the CAR-modified T cells of the present invention to a subject in need of the treatment.

[0182] The CAR-modified T cells of the present invention can be administered alone or as a pharmaceutical composition in combination with a diluent and / or other components such as IL-2, IL-17, or other cytokines or cell populations. In short, the pharmaceutical compositions of the present invention may comprise target cell populations as described herein, combined with one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients. Such compositions may comprise buffers such as neutral buffered saline, sulfate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose, or dextran, mannitol; proteins; peptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The compositions of the present invention are preferably formulated for intravenous administration.

[0183] The pharmaceutical compositions of the present invention can be administered in a manner suitable for the disease to be treated (or prevented). The amount and frequency of administration will be determined by factors such as the patient's condition, and the type and severity of the patient's disease—although the appropriate dosage can be determined by clinical trials.

[0184] When referring to "effective dose," "immunologically effective dose," "antitumor effective dose," "tumor-suppressive effective dose," or "therapeutic dose," the precise amount of the composition of the invention to be administered can be determined by a physician, taking into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and disease condition. It can generally be indicated that: pharmaceutical compositions comprising T cells described herein can be administered in doses of 10... 4 Up to 10 9 A dose of cells / kg body weight, preferably 10. 5 Up to 10 6 The T-cell composition can be administered at a dose of cells per kg of body weight (including all integer values ​​within those ranges). These doses can also be administered multiple times. The cells can be administered using infusion techniques known in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The optimal dose and treatment regimen for a specific patient can be readily determined by a physician skilled in the medical field by monitoring the patient's disease signs and thus adjusting the treatment accordingly.

[0185] The application of the target composition can be performed in any convenient manner, including by spraying, injection, swallowing, infusion, implantation, or transplantation. The compositions described herein can be administered to patients subcutaneously, intradermally, intratumorally, intranodally, intraspinally, intramuscularly, intravenously (iv), or intraperitoneally. In one embodiment, the T-cell composition of the present invention is administered to a patient by intradermal or subcutaneous injection. In another embodiment, the T-cell composition of the present invention is preferably administered by intravenous injection. The T-cell composition can be injected directly into the tumor, lymph node, or site of infection.

[0186] In some embodiments of the invention, cells activated and expanded using the methods described herein or other methods known in the art for expanding T cells to therapeutic levels are administered to a patient in combination with any number of relevant therapeutic modalities (e.g., before, simultaneously with, or after), including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, cytarabine (also known as ARA-C), or nastatinumab treatment for MS patients or erfaizumab treatment for psoriasis patients or other treatments for specific tumor patients. In further embodiments, the T cells of the invention may be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and FK506, antibodies, or other immunotherapeutic agents. In further embodiments, the cell composition of the invention is administered to a patient in combination with bone marrow transplantation, chemotherapy agents such as fludarabine, external beam radiotherapy (XRT), or cyclophosphamide (e.g., before, simultaneously with, or after). For example, in one embodiment, the subject may undergo standard treatment with high-dose chemotherapy followed by peripheral blood stem cell transplantation. In some embodiments, the subject receives an injection of the expanded immune cells of the present invention after transplantation. In an additional embodiment, the expanded cells are administered before or after surgery.

[0187] The dosage of the above treatments administered to patients will vary depending on the precise nature of the condition being treated and the recipient of the treatment. The dosage ratios administered to individuals can be implemented according to accepted practices in the field. Typically, 1 × 10⁻⁶ ppm can be administered per treatment or per course of treatment. 6 One to 1×10 10 The CAR-T cells of the present invention are administered to a patient via, for example, intravenous infusion.

[0188] The main advantages of this invention include:

[0189] 1) This invention constructs CAR-T cells containing PD1-4-1BB signaling molecules, which convert PD1-PDL1 immunosuppressive signals into T cell stimulation signals, significantly enhancing the killing power of CAR-T cells against PD-L1 positive tumors.

[0190] 2) The CAR molecule of the present invention uses the CD28 co-stimulatory domain, and the PD1-4-1BB signaling conversion molecule uses the 4-1BB co-stimulatory domain. Unexpectedly, the two can share the CD3ζ domain. The resulting CAR-T cells can achieve early high activation and secrete a large amount of cytokines, and can also maintain long-lasting killing power after multiple rounds of immune stimulation.

[0191] 3) This invention screened CAR molecules and signal transducers with different structures and found that the in vivo antitumor effect of CAR molecules using the CD28 co-stimulatory domain and PD1-4-1BB signal transducers using the 4-1BB co-stimulatory domain was better than that of CAR molecules using the 4-1BB co-stimulatory domain and PD1-CD28 signal transducers using the CD28 co-stimulatory domain.

[0192] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and parts by weight.

[0193] Materials and methods:

[0194] plasmid construction

[0195] The variable region fragments (VL and VH) of the light and heavy chains of the anti-B7-H3 monoclonal antibody 376.96 were amplified by PCR, then digested with NcoI and MluI, and cloned into the SFG retroviral vector backbone to construct the SFG-376.96-CD8-CD28-CD3ζ (B7-H3-28ζ-CAR) vector; wherein CD8 is the CD8α hinge region and transmembrane domain, CD28 is the intracellular co-stimulatory domain of CD28, and CD3ζ is the intracellular domain of CD3ζ. Figure 1 A).

[0196] Using T-cell cDNA as a template, the extracellular coding sequence of the PD1 gene (GeneBank: NM_005018.3) was amplified by PCR. A self-cleaving peptide 2A and a signal peptide SP were introduced at the N-terminus of the PD1 gene's extracellular sequence via fusion PCR. A Flag tag was added to the C-terminus, followed by a homologous mutation in CD8, and then a 4-1BB sequence was added, resulting in 2A-SP-PD1-Flag-CD8(m)-BB. This sequence was then double-digested with SalI and XhoI and cloned into the SFG-376.96-CD8-CD28-CD3ζ vector, namely SFG-376.96-CD8-CD28-CD3ζ-2A-SP-PD1-Flag-CD8α(m)-BB, abbreviated as B7-H3-28ζ-PD1-BB-CAR. CD8 represents the CD8α hinge region and transmembrane domain, CD28 is the intracellular costimulatory domain of CD28, CD3ζ is the intracellular domain of CD3ζ, CD8(m) is a codon-synonymous mutation of the CD8α hinge region and transmembrane domain to prevent recombination with the CD8 sequence in B7-H3-28ζ-CAR, and BB is the intracellular costimulatory domain of 4-1BB. Figure 1 A).

[0197] Preparation of retroviruses expressing B7-H3-28ζ-2A-PD1-BB dual-target CAR

[0198] 2×10 6 293T cells were seeded in 10cm cell culture dishes, and virus packaging was performed 24 hours later. The specific steps were as follows: 30μL of GeneJuice transfection reagent (Merck Millipore) was added to 470μL of serum-free IMDM medium and mixed well, then incubated at room temperature for 5 min. During this time, a 1.5mL EP tube was prepared, and 4μg of B7-H3-28ζ-CAR plasmid or B7-H3-28ζ-2A-PD1-BB CAR plasmid, 4μg of PeqPam-3 plasmid, and 2μg of RDF plasmid were mixed. The plasmid mixture was then mixed with GeneJuice transfection reagent, incubated at room temperature for 15 min, and then transfected into 293T cells. 48h after transfection, the culture supernatant containing retroviruses was collected, filtered through a 0.45μm filter, aliquoted, and frozen at -80℃ for later use. Add 12 mL of fresh IMDM complete medium to the culture dish and continue culturing for 24 h. Collect the viral supernatant after 72 h, filter, aliquot, and freeze at -80℃ for later use.

[0199] Preparation and in vitro expansion of CAR-T cells

[0200] PBMC lymphocytes were isolated from the peripheral blood of healthy volunteers and then added to 24-well plates coated with CD3 and CD28 antibodies at a density of 1.5 × 10⁻⁶. 6 Cells were placed in each well, and after 24 hours of stimulation, IL-7 (10 ng / mL) and IL-15 (5 ng / mL) were added, and stimulation was continued for another 24 hours. T cells were collected and counted for later use. The stimulated T cells were then infected with the recombinant retrovirus described above. The specific infection steps were as follows: 1 mL of supernatant expressing B7-H3-28ζ-CAR or B7-H3-28ζ-PD1-BB-CAR was added to a 24-well plate coated with retrovirus, centrifuged at 2000g for 1.5 hours, and the supernatant was discarded after centrifugation. 5 × 10⁶ cells were added to the plate. 5 Stimulated T cells were centrifuged at 1000g for 10 minutes and cultured in a 37°C cell culture incubator. The culture medium was replaced with fresh medium after 48 hours, and thereafter changed every two days. Four days after infection, 3 × 10⁶ cells were collected. 5 Cells were stained with anti-Fab antibody (Jackson Immuno Research Laboratories) to detect CAR expression on the surface of CAR-T cells, and PD1 expression was detected with anti-Flag antibody (Biolegend). Figure 1 (See result B). Twelve days later, CAR-T cells were collected to assess their cytotoxic function.

[0201] Constructing target cells overexpressing PD-L1

[0202] Using T cell cDNA as a template, the full-length cDNA sequence of the PD-L1 gene was amplified by PCR, and PD-L1 was cloned into the pLVX-EF1α-PGK-Puro vector by double digestion with EcoRI and XbaI. The virus was then coated onto 293T cells. First, a control cell line expressing only GFP (MB231) was constructed. Based on the control cell line, a target cell line stably overexpressing PD-L1 (MB231-PD-L1) was constructed. Figure 2 B).

[0203] Multiple rounds of co-culture killing experiments

[0204] One day in advance, breast cancer cells MB231 and MB231-PD-L1 were injected at a dose of 2.5 × 10⁻⁶. 5 Add the cells to each well of a 24-well cell culture plate and incubate overnight. Once the cells have adhered, add 5 × 10⁵ cells per well. 4NT (Non-transduced), B7-H3-28ζ-CAR-T, or B7-H3-28ζ-PD1-BB-CAR-T cells were used, with a T cell to tumor cell ratio of 1:5. Two replicates were performed per co-culture round. Supernatant was collected on days 1 and 3 of the first co-culture round, and supernatant was collected after 24 hours for each subsequent co-culture round.

[0205] The co-culture cycles ended on days 4, 7, 11, 14, and 17. One day prior, breast cancer cells MB231 and MB231-PD-L1 were cultured at a rate of 2.5 × 10⁻⁶. 5 Add cells to each well of a 24-well cell culture plate and incubate overnight. On the day of co-culture, collect half of the T cells from the previous round of co-culture wells and transfer them to the corresponding new 24-well plates. Figure 3 A). Collect cells from another duplicate well of the previous co-culture, remove dead cells with Zombie Aqua Dye (Biolegend), add CountBright absolute counting beads (Thermo Scientific) for counting, and analyze T cells (CD3+) by flow cytometry. + ) and tumor cells (GFP) + )quantity( Figure 3 B).

[0206] ELISA

[0207] In the above-mentioned multi-round co-culture killing experiment, the supernatant was collected on days 1 and 3 of one round of co-culture, and for each of the remaining rounds of co-culture for 24 hours. The release of these two cytokines in the co-culture supernatant was detected using an IFN-γ and IL-2 ELISA kit (Mabtech) and in accordance with the kit instructions.

[0208] Flow cytometry

[0209] In the co-culture system, T cells were labeled with APC-CD3 antibody, tumor cells were labeled with GFP, and the expression level of CAR molecules was labeled with anti-Fab antibody. Dead cells were removed with Zombie Aqua Dye (Biolegend), and CountBright absolute counting beads (Thermo Scientific) were added for counting. The labeled samples were detected by BD FACSCanto II flow cytometer using BD Diva software (BD Biosciences). At least 10,000 live cells were collected for each sample, and the collected data were analyzed using Flowjo 10 software.

[0210] Example 1 Plasmid Construction

[0211] The extracellular domain of the PD1 gene was cloned, along with the hinge and transmembrane regions of CD8 (with a tandem codon synonymous mutation) and the intracellular costimulatory domain of 4-1BB. These were then ligated to the B7-H3-28ζ plasmid via a 2A sequence to construct the B7-H3-28ζ-PD1-BB-CAR plasmid. Figure 1 A). B7-H3-28ζ-CAR and B7-H3-28ζ-PD1-BB-CAR molecular plasmids were packaged into retroviruses and used to infect T cells isolated from peripheral blood of healthy individuals to prepare CAR-T cells. The infection efficiency was approximately 90% in both cases. Figure 1 B,C) indicates that B7-H3-28ζ-PD1-BB-CAR-T cells can be successfully constructed in vitro and are not significantly different from B7-H3-28ζ-CAR-T cells.

[0212] Example 2: Multi-round co-culture killing experiment

[0213] The breast cancer cell line MB231 was selected as the target cell to verify the function of B7-H3-28ζ-PD1-BB-CAR-T cells. B7-H3 was highly expressed in MB231 cells, but after IFN-γ stimulation, MB231 cells showed low expression of PD-L1. Therefore, an MB231 cell line overexpressing PD-L1 (MB231-PD-L1) was constructed for in vitro co-culture experiments. Figure 2 A, B).

[0214] 2.1 Tumor cell killing effect

[0215] To test the effectiveness of B7-H3-28ζ-PD1-BB-CAR-T against PD-L1 + To assess the ability of tumor cells to multiply, MB231 and MB231-PD-L1 cells were co-cultured with NT, B7-H3-28ζ-CAR-T, and B7-H3-28ζ-PD1-BB-CAR-T cells in multiple rounds, with two replicates per round. In the first round of co-culture, the ratio of T cells to tumor cells was 1:5. On days 4, 7, 11, 14, and 17, half of the T cells from one well of the previous co-culture were collected and added to tumor cells that had been seeded one day in advance. Figure 3 A). Collect all cells from another well and analyze T cells (CD3+) by flow cytometry. + ) and tumor cells (GFP) + )quantity( Figure 3(B) The results showed that in the first and second rounds, both types of CAR-T cells could effectively eliminate wild-type and PD-L1-overexpressing MB231 cells. From the third round onwards, the ability of B7-H3-28ζ-CAR-T cells to eliminate MB231 cells gradually decreased, and in the fourth and fifth rounds, B7-H3-CAR-T cells were almost undetectable. However, B7-H3-28ζ-PD1-BB-CAR-T cells could still completely eliminate MB231-PD-L1 cells in the third and fourth rounds.

[0216] It is noteworthy that in the third round of co-culture experiments, B7-H3-28ζ-CAR-T cells could completely eliminate MB231, while a large number of tumor cells remained in the co-culture system with MB231-PD-L1. This indicates that PD-L1 does indeed inhibit the tumor-killing ability of CAR-T cells. Furthermore, B7-H3-28ζ-CAR-T cells carrying the PD1-BB receptor can convert the inhibitory signal of PD1 / PD-L1 into a T-cell activating signal, thereby continuously eliminating MB231-PD-L1 cells until the fifth round of co-culture. Figure 3 B).

[0217] 2.2 Cell counting results

[0218] Cell count results in each round of co-culture and Figure 3 B-flow cytometry Figure 1 In the first round, B7-H3-28ζ-CAR-T and B7-H3-28ζ-PD1-BB-CAR-T were co-cultured with two cell lines, and there was no significant difference in the number of CAR-T cells. Figure 4 From the second to the fifth round, the number of B7-H3-28ζ-PD1-BB-CAR-T cells was significantly higher than that of B7-H3-28ζ-CAR-T cells. In the first and second rounds, there was no significant difference in the number of remaining tumor cells between the B7-H3-28ζ-CAR-T and B7-H3-28ζ-PD1-BB-CAR-T co-culture systems. From the third to the fifth round, the number of remaining tumor cells in the B7-H3-28ζ-CAR-T co-culture system was higher than that in the B7-H3-28ζ-PD1-BB-CAR-T co-culture system. Figure 5From the third round onwards, the number of B7-H3-28ζ-CAR-T cells decreased, and their ability to clear MB231-PD-L1 gradually declined. However, B7-H3-28ζ-CAR-T cells carrying PD1-BB could convert the inhibitory signal of PD1 / PD-L1 into a T cell activating signal, thereby continuously expanding and clearing MB231-PD-L1 cells up to the fifth round. These data indicate that B7-H3-28ζ-PD1-BB-CAR-T cells exhibit a sustained ability to clear tumor cells, maintaining T cell activity and function even under repeated antigen stimulation, and this function depends on the interaction of PD1 / PD-L1.

[0219] 2.3 Cytokine release levels

[0220] The trend of cytokine release was generally consistent with the cell counting results. In each round of co-culture experiments, the amount of IFN-γ released by B7-H3-28ζ-PD1-BB-CAR-T cells was higher than that released by B7-H3-28ζ-CAR-T cells. Particularly from the second round onwards, the amount of IFN-γ released by B7-H3-28ζ-PD1-BB-CAR-T cells co-cultured with MB231-PD-L1 was the highest, indicating that PD1-BB enhanced the anti-tumor effect of CAR-T cells and was dependent on the interaction between PD1 and PD-L1. Data from day 3 and the second round showed that B7-H3-28ζ-CAR-T cells co-cultured with MB231-PD-L1 tumor cells secreted less IFN-γ compared to co-cultured with MB231, indicating that PD-L1 inhibits the secretion of cytokines by CAR-T cells. Figure 6 IL-2 release was low, almost undetectable from the second to the fifth round. In the first round of co-culture experiments, the amount of IL-2 released was higher than that of B7-H3-28ζ-CAR-T, and the highest IL-2 release was observed in the co-culture system of B7-H3-28ζ-PD1-BB-CAR-T cells and MB231-PD-L1, indicating that PD1-BB can effectively activate CAR-T cells and depends on the interaction between PD1 and PD-L1. Data from day 1 and day 3 show that when B7-H3-28ζ-CAR-T cells were co-cultured with MB231-PD-L1 tumor cells, less IL-2 was secreted compared to co-culture with MB231, indicating that PD-L1 inhibits CAR-T cell activation. Figure 7 ).

[0221] Example 3: In vivo antitumor activity verification

[0222] To further verify the anti-tumor effect of B7H3-28ζ-PD1-BB-CAR-T cells in vivo, the MDA-MB-231-PD-L1 breast cancer metastasis model was used to detect the in vivo anti-tumor activity of B7H3-28ζ-PD1-BB-CAR-T cells. Figure 8 A). Simultaneously, B7-H3-BBζ-CAR-T cells carrying the PD1-CD28 chimeric receptor (B7H3-BBζ-PD1-28-CAR-T) were constructed for parallel comparison. Compared to the B7-H3-CAR-T group, B7-H3-CAR-T cells carrying either the PD1-BB or PD1-28 chimeric receptors exhibited better tumor growth inhibition. Furthermore, the B7-H3-CAR-T treatment group carrying the PD1-BB chimeric receptor showed superior efficacy compared to the B7-H3-CAR-T group carrying the PD1-28 chimeric receptor, with lower tumor fluorescence signal and longer survival time in mice. Figure 8 These experiments demonstrate that B7H3-28ζ-PD1-BB is the optimal construction method, which overcomes the inhibitory signaling of PD1 / PD-L1 and maintains the CAR-T activation signal at an appropriate level, significantly enhancing CAR-T persistence and anti-tumor activity both in vivo and in vitro.

[0223] Example 4: PD1-BB chimeric receptor shares CD3ζ with CAR molecules

[0224] To investigate whether CAR-T cells carrying the PD1-BB chimeric receptor can target and kill tumor cells by recognizing PD-L1 through sharing CD3ζ in the CAR molecule, PD1-BB-CAR and PD1-BBζ-CAR were additionally constructed. Figure 9 A), and successfully prepared the corresponding CAR-T cells. The results showed that the infection rate was around 90%, and the expansion was basically the same. Figure 9 BD).

[0225] MDA-MB-453 cells do not express B7H3, and IFN-γ stimulation also fails to express PD-L1. Based on this, MDA-MB-453 cells overexpressing PD-L1 (MDA-MB-453-PD-L1) were constructed. Figure 10 (A, B). This cell line will be used to verify whether PD1-BB can kill PD-L1 positive tumor cells by sharing CD3ζ with B7H3-CAR in B7H3-28ζ-PD1-BB-CAR-T cells.

[0226] The results showed that PD1-BB, PD1-BBζ, B7H3-28ζ, and B7H3-28ζ-PD1-BB CAR-T cells could not kill wild-type MDA-MB-453 cells; PD1-BB-CAR-T and B7H3-28ζ-CAR-T cells could not kill PD-L1-overexpressing MDA-MB-453 cells, while B7H3-28ζ-PD1-BB-CAR-T cells could kill PD-L1-overexpressing MDA-MB-453 tumor cells. Figure 10 C). This indicates that the PD1-BB receptor in B7H3-28ζ-PD1-BB-CAR-T cells can kill PD-L1-positive but B7-H3-negative tumor cells by sharing CD3ζ with B7H3-CAR, thus preventing tumor antigen escape.

[0227] sequence:

[0228] 1.PD1:

[0229] PD1 DNA sequence:

[0230] ATGGAGTTTGGGCTGAGCTGGCTTTTTCTTGTGGCTATTTTAAAAGGTGTCCAGTGCTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCA GCCCGCCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTG (SEQ ID NO:1)

[0231] PD1 amino acid sequence:

[0232] MEFGLSWLFLVAILKGVQCFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLV(SEQ ID NO:2)

[0233] 2. CD8α(m):

[0234] DNA sequence of CD8α(m) hinge region and transmembrane region:

[0235] ACCACCACACCAGCTCCTCGGCCACCTACTCCAGCTCCAACAATTGCCAGCCAGCCACTGTCTCTGAGGCCCGAAGCTTGTAGACCTGCTGCTGGCGGAGCCGTGCATACAAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCTGGAACATGCGGAGTTCTGCTGCTGAGCCTGGTCATCACCCTGTACTGT(SEQ ID NO:3)

[0236] Amino acid sequence of CD8α(m) hinge region and transmembrane region:

[0237] TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC(SEQ ID NO:4)

[0238] 3. CD8α:

[0239] DNA sequence of CD8α hinge region and transmembrane region:

[0240] ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC(SEQ ID NO:5)

[0241] Amino acid sequences of the CD8α hinge region and transmembrane region:

[0242] TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC(SEQ ID NO:4)

[0243] 4.4-1BB:

[0244] DNA sequence of the 4-1BB intracellular co-stimulatory domain:

[0245] AAACGGGGCAGAAAGAAACTCCGTATATATTCAAACAACCATTTAT GAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTC CAGAAGAAGAAGAAGGAGGATGTGAACTG (SEQ ID NO: 6)

[0246] The amino acid sequence of the 4-1BB intracellular co-stimulatory domain:

[0247] KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL(SEQ ID NO:7)

[0248] 5. Complete PD1-CD8α(m)-4-1BB sequence:

[0249] DNA sequence:

[0250] ATGGAGTTTGGGCTGAGCTGGCTTTTTCTTGTGGCTATTTTAAAAGGTGTCCAGTGCTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGACCGCAGCCAGCCCGGCCAGGACTGCCGCTTCCGTGTCACACAACTGCCCAACGGGCGTGACTTCCACATGAGCGTGGTCAGGGCCCGGCGCAATGACAGCGGCACCTACCTCTGTGGGGCCATCTCCCTGGCCCCCAAGGCGCAGATCAAAGAGAGCCTGCGGGCAGAGCTCAGGGTGACAGAGAGAAGGGCAGAAGTGCCCACAGCCCACCCCAGCCCCTCACCCAGGCCAGCCGGCCAGTTCCAAACCCTGGTGGGATCCGACTACAAGGATGACGACGACAAGGGTGGTGCATGCACCACCACACCAGCTCCTCGGCCACCTACTCCAGCTCCAACAATTGCCAGCCAGCCACTGTCTCTGAGGCCCGAAGCTTGTAGACCTGCTGCTGGCGGAGCCGTGCATACAAGAGGACTGGATTTCGCCTGCGACATCTACATCTGGGCCCCTCTGGCTGGAACATGCGGAGTTCTGCTGCTGAGCCTGGTCATCACCCTGTACTGTAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG(SEQ ID NO:8)

[0251] Amino acid sequence:

[0252] MEFGLSWLFLVAILKGVQCFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVP TAHPSPSPRPAGQFQTLVGSDYKDDDDKGGACTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL(SEQID NO:9)

[0253] 6. The amino acid sequence of the antigen-binding fragment of B7-H3

[0254] MEFGLSWLFLVAILKGVQCDIVMTQSHKFMSTSIGARVSITCKASQDVRTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYGTPPWTFGGGTKLEIKGGGG SGGGGSGGGGSEVQLVESGGGLVKPGGSLKLSCEASRFTFSSYAMSWVRQTPEKRLEWVAAISGGGRYTYYPDSMKGRFTISRDNAKNFLYLQMSSLRSEDTAMYYCARHYDGYLDYWGQGTTLTVSS(SEQ ID NO:10)

[0255] 7. Self-cleaving peptide T2A DNA sequence

[0256] GGAAGCGGAGAGGGCAGGGGAAGTCTTCTAACATGCGGGGACGTGG AGGAAAATCCCGGGCCT(SEQID NO:11)

[0257] All documents mentioned in this invention are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that after reading the foregoing teachings of this invention, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by the appended claims.

Claims

1. A signal conversion molecule, characterized in that, The signal conversion molecule includes: i) Extracellular domains of the PD1 molecule; ii) Hinge region and transmembrane region; and iii) Intracellular co-stimulatory domain derived from 41BB.

2. The signal conversion molecule as described in claim 1, characterized in that, The signal conversion molecule described has the structure shown in Formula I: PT-IC-CD3ζ(I) In the formula, Each "-" independently represents a linking peptide or peptide bond; P is the extracellular domain of the PD1 molecule; T represents the hinge region and the transmembrane region; IC is an intracellular co-stimulatory domain; CD3ζ is a cytoplasmic signaling sequence that is absent or derived from CD3ζ.

3. The signal conversion molecule as described in claim 1, characterized in that, The amino acid sequence of the signal conversion molecule is shown in SEQ ID NO:

9.

4. A nucleic acid molecule, characterized in that, The nucleic acid molecule comprises a polynucleotide encoding the signal transduction molecule as described in claim 1.

5. The nucleic acid molecule as described in claim 4, characterized in that, The nucleic acid molecule further contains a polynucleotide encoding a chimeric antigen receptor (CAR), preferably, the chimeric antigen receptor targets B7-H3.

6. The nucleic acid molecule as described in claim 5, characterized in that, The signal transducer molecule has an intracellular co-stimulatory domain derived from 4-1BB, and the CAR has an intracellular co-stimulatory domain derived from CD28.

7. A carrier, characterized in that, The carrier contains the nucleic acid molecule as described in claim 4.

8. An engineered immune cell, characterized in that, The immune cells contain the vector as described in claim 7 or the chromosome in which the exogenous nucleic acid molecule as described in claim 4 is integrated, or express the signal transduction molecule as described in claim 1.

9. The immune cells as described in claim 8, characterized in that, The immune cells express the signal transduction molecules and chimeric antigen receptors (CARs).

10. The immune cells as described in claim 9, characterized in that, The signal transducer molecule has an intracellular co-stimulatory domain derived from 4-1BB, and the CAR has an intracellular co-stimulatory domain derived from CD28.

Citation Information

Patent Citations

  • Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof

    US5350674A

  • Gene therapy

    US5399346A

  • Delivery of exogenous DNA sequences in a mammal

    US5580859A

  • Adenovirus vectors for gene therapy

    US5585362A

  • Induction of a protective immune response in a mammal by injecting a DNA sequence

    US5589466A